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Abstract
Background
Prostate cancer (CaP) has a rising number of patients requiring routine follow up. In this study, 
we aimed to test a computer led follow up service for prostate cancer in two UK hospitals. The 
testing aimed to validate the computer Expert system in making clinical decisions according 
to the individual patient’s clinical need. The valid model should accurately identify patients 
with disease recurrence or treatment failure based on their blood test and clinical picture. 
Methods
A clinical decision support system (CDSS) was developed from European (EAU) and national 
(NICE) guidelines along with knowledge acquired from Urologists. This model was then 
applied in two UK hospitals to review patients post CaP treatment. These patients’ data (n= 
200) were then reviewed by two independent Urology consultants (blinded from the CDSS 
and other consultant’s rating) and the agreement was calculated by kappa statistics for 
validation. The second objective aimed to verify the system by estimating the system 
reliability. 
Results
The two individual urology consultants identified 12 % & 15% of the patients to have potential 
disease progression and recommended their referral to the Urology care. The kappa coefficient 
for the agreement between the CDSS and the 2 consultants was 0.81 (p < 0.001) and 0.84 (p < 
0.001). The agreement among both specialist was also high with k = 0.83 (p < 0.001). The 
system reliability was estimated on all cases and this demonstrated 100% repeatability of the 
decisions.  
Conclusion
The computer led follow up is a valid model for providing safe follow up for prostate cancer. 
1.1 Introduction
Prostate cancer is the most common malignant disease in men and the third leading cause of 
cancer related mortality in the United Kingdom in 2014 (1). It is a disease of the elderly, with 
men above the age of 75 at higher risk of disease related mortality (2). It has a heterogeneous 
course of progression from slow growing and potentially insignificant, to aggressive with 
serious impact on the patient’s health and quality of life. Despite the disease rising prevalence, 
there has been a significant improvement in survival rates (3, 4) which may be accounted for 
by the availability of more accurate diagnostic and treatment modalities. However, where best 
to safely follow up patients remains unresolved. The current National Institute of for Health 
and Care Excellence (NICE) recommendation is to provide this follow up in primary care 
where appropriate (5). However, this recommendation was met with concerns from both  GPs 
and Urologists because of the lack of expertise in the community (6). The National Prostate 
Cancer Audit 2014 annual report identified five different models for prostate cancer follow up: 
Consultant-led clinic, Cancer Nurse Specialist (CNS)-led clinic, Telephone clinic, 
Community-based specialist follow up and Radiographer-led clinic (only for radiotherapy 
pathway) (7). The community based model played only a minor role in follow up in this audit. 
In various industries and expert simulating systems have provided an alternative cheap, reliable 
and available solution where expertise is lacking (8). The bottleneck to their development is 
the knowledge acquisition phase, which usually is exhaustive and time consuming (9). 
Furthermore, the system has to go through rigorous testing; system validation (are we building 
the right system?) and system verification (are we building the system correctly. Previous 
attempts to apply this to an industry setting have suffered from a lack of consistency and 
formality in the model (10). The same problems were also evident in medical expert system 
development and has challenged their uptake in health care (11).  
In this study we aimed to verify and validate an expert system simulating a Urologist in the 
follow up of stable prostate cancer and its application in supporting GPs in providing a follow 
up service in the community. Therefore, we tested the null hypothesis that the agreement 
between the expert system and the human domain experts is slight to fair (k0 = 0.4) against the 
alternative that it is better than moderate (k1 > 0.61). For verification, the expert system has to 
be 100 percent reliable i.e. the same clinical input triggered the system to produce the exact 
same outputs on each occasion.
1.2 Methods  
1.2.1 Description of the prostate cancer system 
The Clinical Decision Support System (CDSS) is a web based solution that can be used with 
current versions of browsers including Microsoft IE, Google Chrome, Mozilla and Safari. At 
the core of the system is a Rule Engine which processes all of the data captured and held for a 
patient and presents it to a complex disease domain specific algorithm compiled and tested in 
accordance with NICE guidelines (5). The system uses principally Microsoft technologies 
including MS SQL Server database, the Microsoft.NET development framework and the C# 
programming language along with other web technologies like JavaScript and AJAX.
1.2.2 System security and functional analysis
The expert system is based on a secure remote server held within the NHS IT network (N3). 
This location makes it accessible to all NHS primary and secondary care sites and NHS 
partners without the need for individual copies at each site, providing one single point of 
access. Only authorised personnel can gain access to this system and all the stored data are 
encrypted in line with the standards of the Information Governance Statement of Compliance 
(IG SoC).  
The system is triggered by an authorised user query about a patient visit. The CDSS access 
their records on the Hospital Information System, including their laboratory test results, before 
asking the user to fill a problem specific online form. The form includes routine questions 
enquiring about relevant symptoms as outlined in the NICE 2014 guidelines to support the 
system accurate decision making (5). The system output is in the form of an electronic clinic 
letter suggesting a tailored treatment plan for the individual patient consultation.  
1.2.3 Study configuration
The CDSS is already part of an existing Clinical Nurse Specialist (CNS) led CaP follow up 
service in Derby Hospital NHS Foundation trust and University Hospitals Coventry and 
Warwickshire NHS Trust. The main system function in this service is acting as an intelligent 
database and clinic letter generator (figure 1 and figure 2). Patients included were those who 
had their disease diagnosed and treated by the urology cancer multidisciplinary team before 
being discharged for follow up to the CNS clinic. There were no specific criteria for follow up 
in this clinic and the clinic predated the software. 
When seeing a patient for follow up the users (CNS in this study) supply the CDSS with recent 
symptoms and blood test results, and the system produces an electronic letter stating significant 
clinical details and a suggested treatment plan. The treatment plan was reviewed and 
overridden by the CNS if appropriate to do so. 
In this study, we only aimed to evaluated the system validity, thus the letters were anonymised 
and the nurses’ plans were eliminated before examining the cases against the inclusion criteria. 
Each letter generated by the CDSS had five main components (figure 1 & figure 2):
1. History of disease and treatment.
2. Current symptoms and blood test results.
3. System analysis of clinical data.
4. System suggested outcome.
5. Nurse note’s text box for supplying any extra information and overriding the system 
decision where necessary. 
The eligible cases were anonymised by eliminating all patients’ identifiers and the CNS free 
text entry of their own clinical assessment and plan (component 5 in figure 2)
Cases were examined by the study clinical monitor against the inclusion criteria and cases 
were excluded from the study with justification (as not enough clinical data, newly diagnosed 
or treated cases i.e. not CaP etc.).  
1.2.3.1 Eligibility criteria
All adult patients seen in this clinic with known prostate cancer whom had their primary 
treatment assigned and delivered. 
1.2.3.2 Inclusion criteria
Adult patients with known CaP and presenting for routine follow up in clinic with (essential 
requirement): 
• Known prostate cancer treatment pathway.
• Details on his Prostate specific antigen serum levels (PSA) on presentation and 
most recent results. 
With or without (optional requirement):
• Disease or treatment related symptoms (lower urinary tract, bone pain, weight loss 
and erectile dysfunction)  
• Abnormal blood test (haemoglobin, calcium, urea, electrolytes, creatinine, and liver 
function tests)
1.2.3.3 Exclusion criteria
• Cases with newly diagnosed prostate cancer that are waiting for decision to treat.
• Cases with known prostate cancer that are being evaluated for known recent disease 
progression.
• Cases with no clinical details of their initial cancer presentation such as Gleason 
score, PSA, and tumour grade which would influence the follow up decision 
making.  
In order to reach both end points, the study divided into two branches after case selection 
(figure 3). In the primary end point pathway, the included cases were reviewed by two 
independent clinical investigators after eliminating the system analysis and suggestions 
(Components 3 and 4 samples in figure 1). Each investigator independently assigned an 
outcome for each case (figure 4) according to the disease history, current results and symptoms 
blinded from the system recommendation. 
In the second part of the study, the system reliability and precision was estimated by codifying 
all cases clinical variables and output. The cases specific codes were all tabulated on a spread 
sheet (Excel, Microsoft Corp, Seattle) and all cases with similar input(s) were expected to have 
the same output code. In case of discrepancy, errors were identified and the system was then 
corrected. Any system changes were followed by a retest by a new sample of cases to re-
estimate reliability until 100% precision was obtained (secondary end point).
1.2.4 Statistical evaluation 
The system validation was estimated by testing the null hypothesis that the agreement between 
the CDSS and the human domain experts was slight to fair (k0 = 0.4) against the alternative 
that it was better than moderate (k1 > 0.61) (12). Kappa was estimated between each 
investigator (INV1 & INV2) and then the CDSS between both investigators.
1.3 Results 
The study included data of 200 patients seen in either hospitals (100 each). All patients had 
CaP and mean and median age was 75 (range 51 to 94) with a mean and mode Gleason score 
of 7. The risk stratifications according to D’Amico’s classification (13) of their disease on 
diagnosis demonstrated 96 (48%) patients in the high risk group and 78 (39%) & 26 (13%) in 
the intermediate and low risk group respectively (figure 5). Radiotherapy had been used to 
treat 128 cases out of the total (figure 6). 
Kappa statistics were estimated to test the hypothesis. The unweighted kappa for INV1 INV2 
was 0.8, and with quadratic weighting the kappa remained, demonstrating substantial 
agreement between CDSS and investigator at 0.86 and 0.96 respectively for INV1 and INV2 
respectively. This refuted the null hypothesis as k0 > 0.4 and alternative hypothesis k1 > 0.6 
was accepted with the conclusion that the CDSS is validation and its assigned outcomes are 
acceptable by the domain experts (tables 1, 2 & 3). 
Both investigators identified 31 cases with possible disease progression or recurrence (INV1 
= 25, INV2 = 29). Most of those cases were biochemical failure (BCF) post radiotherapy 
treatment (21 out of the total of 31) based on either ASTRO (14-16) or PHOENIX  (17) criteria 
or both. Six cases were on watchful waiting had either high or rising PSA and were identified 
as disease progression (those patients did not receive any treatment). Two patients had radical 
surgery with detectable PSA and one was treated with hormone ablation, with significant PSA 
doubling time. CDSS identified all of the above cases as disease progression or recurrence 
except one case who was only classified by INV1 as potential recurrence post radiotherapy. 
They had only two consecutive rises in their PSA, thus not identified as BCF by CDSS or 
INV2. 
The reliability testing was estimated by examining the outcome of cases with similar input 
codes. This demonstrated 100% reliability and so the study secondary objective was met. 
1.4 Discussion 
This multicentre study validated and verified a novel CDSS led follow up service that can be 
used in a prostate cancer follow up setting, which could be based in either primary or secondary 
care. This is the first study to combine quantitative methodologies to perform full system 
validation and verification on real patients. This critical test has been lacking in the 
development of medical Expert Systems, and this has led to poor uptake health care because 
of lack of confidence in these systems (11). Standalone software as CDSS are recognised by 
European regulatory bodies as medical devices and they require registration via strict criteria 
(18). These criteria are outlined in the declarations of the International Organization for 
Standardization (ISO) 13485 (quality management systems), 14971 (risk management) and 
62304 (software development cycle). The latter addresses the standards for testing that should 
met in the validation. In this study, we quantified the validity by estimating the kappa statistics 
in a 2 centre live clinical evaluation. Furthermore, the objective reliability testing verified the 
system and completed the development cycle. These quantified tests support the utility of the 
Expert System as it has met state of the art verification and validation methodologies (18). 
It has been estimated that CaP costs more than €8.43 billion across Europe (£0.8 billion in the 
UK) with most spent on treatment in the first year after diagnosis (19). Prostate cancer follow 
up is also expensive overall and cost effective service improvement is much needed.  This cost 
is expected to increase with improvement in disease specific survival and increase in the 
population life expectancy. The CDSS model may be able to safely move follow up in to 
primary care with potentially significant cost saving (6). The system developers believe that 
the valid system can be used by any healthcare worker regardless their Urological background 
with a potential of adopting an interface for direct patient interaction. This could have 
significant benefits and cost savings but given the age group of the patients and lack of 
flexibility of NHS health care, the later would be challenging to implement. 
This type of study is limited by the quality of the clinical data and experience of the human 
experts. The data in our study were all real patients’ data collected in real time clinics from 
two large tertiary and secondary care centres. Furthermore, uncommon and rare presentations 
have been validated in the knowledge validation study. Cases studied were allocated to the 
CNS follow up clinic by the MDT and may explain the low recurrence rate in this study even 
though 48% of the cases were in the high risk group. 
The clinical investigators were both qualified consultants and they received independent 
specialist training. One had special interest in CaP community follow up and had previously 
developed a follow up model for a remote area. The other investigator had an interest in core 
Urology and stone disease. Both were not familiar with the software development and had no 
conflict of interest. The rating was performed blinded from the other investigator and the 
CDSS, thus bias has been eliminated and the agreement calculated by the kappa coefficient 
should be the true agreement. 
In medicine, the validation of an intervention usually requires a comparison against the gold 
standard to estimate the sensitivity and specificity. This is different to expert system validation 
where it is based on the Turing test concept in comparing the machine’s cognitive performance 
to human domain experts (10, 20). Kappa statistics is more appropriate for this type of 
validation as they estimate the agreement between human and machine cognitive function and 
has been applied by other studies to validate expert systems (21, 22). The sensitivity and 
specificity is only accurate if compared the gold standard as histopathology results and this is 
more widely applied by artificial neural networks as they learn directly from data and the role 
of human opinion is limited (9). 
The long term outcome for those cases was not examined as part of this study. The validation 
aimed to estimate the validity of the system reasoning against consultant urologists. The long 
term outcome can be useful to estimate the accuracy of both investigators and the CDSS, 
however this would require long term follow up and more invasive tests. 
1.5 Conclusion
The CDSS demonstrated high validity and accuracy in its decision making. This tool has 
potential for safe use in supporting follow up of surgical oncology in the primary and 
secondary care. Mixed methodology approach is required to perform the mandatory system 
validation and verification. 
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